Compare Incyte Corporation (INCY) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NetEase Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while NetEase Inc trades at $124.27 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 3.3× Incyte Corporation's market cap, and NetEase Inc pays a 2.45% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and NetEase Inc for 73 Days on average.
| INCY | NTES | |
|---|---|---|
Market Cap | $22.85B | $76.09B |
Volume | 1,927,029 | 486,447 |
Sector | Health | Technology |
52-Week High | $129.93 | $152.85 |
52-Week Low | $83.80 | $109.26 |
Typical Hold Time | 33 Days | 73 Days |
Enterprise Value | $18.35B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
NTES trades at $124.24, up 3.01% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with a P/E of 15.92, net income margin of 27.88%, and robust cash flow from operations of $50.74 billion in 2025. Recent earnings were mixed, with a Q2 2026 miss but a Q1 2026 beat. Analyst consensus is strongly bullish with an $168 price target. News highlights focus on earnings results and long-term dividend growth potential.
The outlook for NTES is positive, supported by strong profitability, a healthy balance sheet, and analyst optimism. Key opportunities include revenue growth and AI investments, while risks involve earnings volatility and competitive pressures in the gaming sector. The stock presents a compelling case for growth investors seeking exposure to China's tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
